Guggenheim raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $35 from $34 and keeps a Buy rating on the shares. The firm continues to be “encouraged” by the trajectory of Zoryve and Arcutis’ efforts to maximize its value through commercialization, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $35 from $30 at TD Cowen
- Arcutis Biotherapeutics price target raised to $35 from $32 at Morgan Stanley
- Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating
- Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target
- Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright